Adicet Bio, INC 10-Q quarterly reports

Adicet Bio reports on its Q2 2026 financial and operational progress, highlighting advancements in its gamma delta T cell therapies while managing ongoing operational expenses and cash reserves.

Adicet Bio, Inc. filed its Form 10-Q for the quarter ended March 31, 2026, detailing a net loss of $20.2 million and providing updates on its gamma delta T cell therapies.

Adicet Bio, a clinical-stage biotechnology company, reported its Q3 2025 financial results, highlighted positive preliminary ADI-001 data in autoimmune diseases, and secured $74.8 million in a recent offering, while addressing Nasdaq listing compliance.

Adicet Bio, a clinical-stage biotechnology company, reported increased net losses and a strategic pipeline prioritization, including a 30% workforce reduction, to focus on its lead autoimmune and solid tumor programs.

Adicet Bio, a clinical-stage biotechnology company, announces its financial results for the first quarter of 2025 and provides an update on its clinical development programs.

Adicet Bio, a clinical-stage biotechnology company, released its Q3 2024 financial results, highlighting progress in its gamma delta T-cell therapy programs and providing updates on clinical trials.

Adicet Bio, a clinical-stage biotechnology company, announced its second quarter 2024 financial results, highlighting progress in its gamma delta T-cell therapy programs and recent regulatory milestones.

Adicet Bio reports a net loss of $28 million for the first quarter of 2024, while highlighting progress in clinical trials and pipeline development.